If you have been monitoring your portfolio or researching historical biotech plays, you have likely come across the ticker agrx stock (Agile Therapeutics, Inc.). For years, this micro-cap specialty pharmaceutical developer captured the attention of retail investors and institutional backers alike. Armed with its proprietary Skinfusion® transdermal patch technology and a flagship product, Twirla®, Agile Therapeutics aimed to disrupt the multi-billion-dollar U.S. contraceptive market.
However, if you search your favorite trading platform today for agrx stock, you will find that the ticker is inactive and no longer available for trading. This is because Agile Therapeutics was officially acquired by Spanish global pharmaceutical giant Insud Pharma, S.L. on August 26, 2024.
In this comprehensive analysis, we will conduct a full post-mortem of agrx stock. We will examine the company's ambitious beginnings, the regulatory roller coaster of Twirla's FDA approvals, the commercial headwinds that ultimately drained its cash reserves, the details of the 2024 cash buyout, and what the future holds for Twirla under its new parent company. Whether you are a former shareholder wondering about your cash payout or an investor researching lessons in biotech history, this guide provides all the answers you need.
1. What Happened to AGRX Stock? The August 2024 Acquisition Status
For investors who held shares of Agile Therapeutics, the final chapter of agrx stock unfolded in the summer of 2024. On June 25, 2024, Agile Therapeutics announced that it had entered into a definitive merger agreement to be acquired by Insud Pharma, S.L., a highly respected global pharmaceutical group with operations in over 50 countries.
The transaction closed on August 26, 2024, following a special meeting of stockholders on August 22, 2024, where common shareholders voted overwhelmingly to approve the merger. Under the terms of the agreement, Agile merged with an indirect, wholly-owned subsidiary of Insud (specifically combining with Exeltis USA, Inc., Insud's U.S.-based specialty pharmaceutical division).
Here are the critical financial figures from the acquisition:
- Acquisition Payout: Former common shareholders became entitled to receive $1.52 per share in cash, net of assumed liabilities and estimated transaction costs.
- Total Enterprise Value: The deal valued Agile Therapeutics at approximately $45 million.
- Market Premium: The cash payout of $1.52 per share represented an astronomical 356% premium over the stock's closing price of roughly $0.33 on June 25, 2024, right before the deal was publicly announced.
- Delisting: Upon the completion of the merger on August 26, 2024, Agile common stock immediately ceased trading on the OTCQB venture market and was delisted.
Today, Agile Therapeutics operates as a private, indirect subsidiary of Insud Pharma. As a result, there is no active agrx stock ticker, and the shares can no longer be bought, sold, or traded on any public stock exchange.
2. The Agile Therapeutics Stock Split History: A 1-for-2000 Cumulative Devastation
One of the major sources of confusion for former agrx stock investors is the dramatic decline in their share count over the years. Many retail investors logged into their brokerage accounts in late 2024 only to find they owned a tiny fraction of the shares they originally purchased. To understand why, we have to look at Agile’s extreme reverse stock split history.
To maintain its listing on the NASDAQ and prevent its share price from looking like a worthless penny stock, Agile’s management was forced to execute two consecutive, highly aggressive reverse stock splits:
- The April 27, 2022 Split (1-for-40): Agile implemented a 1-for-40 reverse stock split. If you owned 1,000 shares of AGRX before this date, your position was consolidated into just 25 shares.
- The April 11, 2023 Split (1-for-50): Less than a year later, as the stock price continued to plunge, the company executed another massive 1-for-50 reverse stock split. Your remaining 25 shares were consolidated further, leaving you with just 0.5 shares.
When you combine these two events, the cumulative reverse split ratio was an astonishing 1-for-2000. This means that if you purchased 2,000 shares of agrx stock prior to April 2022, you were left with exactly 1 share by the time of the August 2024 acquisition. While the buyout price of $1.52 per share sounded generous as a premium to the 2024 price of $0.33, anyone who bought before 2022 would have needed a buyout price of thousands of dollars per share just to break even. This dramatic dilution and consolidation is a stark reminder of the risks of holding micro-cap biotech stocks through prolonged cash crunches.
3. The Promise of Twirla and Skinfusion Technology
To understand why agrx stock was once a darling of the micro-cap biotech community, we have to look at the unique medical need the company sought to address. Founded in 1997 and headquartered in Princeton, New Jersey, Agile Therapeutics dedicated itself to developing innovative, non-daily prescription contraceptive products for women.
At the heart of the company's valuation was its proprietary Skinfusion® technology. In the contraceptive market, women historically faced a trade-off. They could take a daily oral pill (which required strict adherence to avoid accidental pregnancy), or they could opt for highly invasive long-acting reversible contraceptives (LARCs) such as intrauterine devices (IUDs) or hormonal implants.
Agile’s Skinfusion technology offered a middle ground: a low-dose, once-weekly transdermal patch. The product, Twirla® (levonorgestrel and ethinyl estradiol), was designed to be applied to the skin (the abdomen, buttock, or upper torso) once a week for three consecutive weeks, followed by a patch-free week.
What made Twirla particularly compelling to clinicians and investors was its active ingredient profile. It was formulated to deliver a low daily dose of estrogen (30 mcg) alongside levonorgestrel, a well-established and trusted progestin with a highly favorable safety profile. At less than 1 millimeter thin, the patch was engineered with a five-layer matrix system designed to optimize wearability and keep the patch securely in place during exercise, showering, and daily movement.
For years, investors in agrx stock believed that if Twirla could secure FDA approval and capture even a small percentage of the massive U.S. contraceptive market, the stock’s upside would be massive. However, the path to commercialization proved to be far more treacherous than anyone anticipated.
4. The Rocky Path to FDA Approval: Defeating Multiple CRLs
The history of agrx stock is a textbook study in the regulatory volatility of biotech investing. Agile's journey to FDA approval for Twirla spanned more than a decade and was marked by devastating setbacks that repeatedly wiped out shareholder value.
Agile initially opened its Investigational New Drug (IND) application for Twirla in 1999, with pivotal Phase 3 trials commencing a decade later. The company submitted its first New Drug Application (NDA) in April 2012. What followed was a series of regulatory roadblocks:
- The First Complete Response Letter (February 2013): The FDA issued a CRL citing significant concerns regarding product quality, manufacturing standards, and clinical trial conduct. This forced Agile back to the drawing board to refine its data.
- The Second Complete Response Letter (December 2017): After years of preparation and an NDA resubmission, the FDA issued a second CRL. This letter highlighted deficiencies relating to quality adhesion test methods and raised questions about the patch's in vivo adhesion properties. Furthermore, the FDA noted regulatory issues at the facility of Agile’s third-party manufacturer, Corium Innovations, Inc.
- The Dispute Resolution and Comparative Wear Study: Refusing to give up, Agile entered formal dispute resolution with the FDA. In 2018, the company agreed to conduct a comparative wear study contrasting Twirla's adhesion with Xulane® (the generic version of Ortho Evra, the dominant patch on the market). This study proved successful, demonstrating that Twirla had acceptable adhesion properties.
- The SECURE Phase 3 Trial: Agile also completed the SECURE Phase 3 trial, which evaluated Twirla in a highly diverse and representative U.S. patient population. The trial demonstrated a Pearl Index of 4.3% in its indicated patient population. Importantly, the trial highlighted a critical limitation: Twirla's efficacy was reduced in women with a Body Mass Index (BMI) between 25 and 30 kg/m2, and it was contraindicated in women with a BMI of 30 kg/m2 or more due to a higher risk of thromboembolism (blood clots).
Finally, on February 14, 2020, the FDA officially approved Twirla. While this was a monumental triumph for the company, the regulatory delays had severely depleted Agile’s financial resources, setting the stage for the commercial struggles that followed.
5. Why Agile Therapeutics Faced Financial Insolvency Post-Approval
In biotech investing, FDA approval is only half the battle. The commercial launch of a new drug requires massive capital, an experienced sales force, and favorable insurance coverage. Agile Therapeutics launched Twirla in late 2020—at perhaps the worst possible moment in modern history.
As the COVID-19 pandemic raged, Agile's sales representatives faced severe restrictions in accessing doctors' offices and clinics. Launching a brand-new women's healthcare product requires face-to-face physician education, which was virtually non-existent during the lockdowns.
To make matters worse, Agile was operating with a heavily leveraged balance sheet. The prolonged regulatory battle had forced the company to repeatedly dilute its equity by issuing new shares of agrx stock, severely eroding the value of early retail investments. The capital required to scale Twirla’s commercialization infrastructure far outstripped the revenue the patch was generating.
Agile spent heavily on marketing, establishing co-promotion agreements (such as an alliance with Afaxys, Inc. to target the public health sector) and managing complex manufacturing terms with Corium Innovations. Despite these efforts, the cash burn rate was unsustainable.
By 2022 and 2023, the financial strain was visible. Agile's stock price plummeted, eventually falling below the NASDAQ minimum bid price requirement. After executing reverse stock splits to temporarily salvage its listing, Agile was eventually demoted to trading on the OTCQB venture market under the same AGRX ticker. It was clear that the company could not survive as an independent, publicly traded entity and desperately needed a well-capitalized partner to take over Twirla’s distribution.
6. Behind the Scenes of the Insud Pharma Cash-Out Merger
Faced with a mounting cash crunch and limited financing options, Agile's board of directors, led by CEO Al Altomari, began exploring strategic alternatives. In mid-2024, they found an ideal suitor in Insud Pharma, S.L.
On June 25, 2024, the companies signed a definitive merger agreement. The deal was structured as a merger of an indirect, wholly-owned subsidiary of Insud (Exeltis Project, Inc.) into Agile, with Agile continuing as the surviving corporation. To keep Agile afloat while the deal was finalized, Insud provided a critical $8 million secured bridge loan backed by Agile’s intellectual property.
The transaction closed on August 26, 2024. For investors holding agrx stock, the buyout represented a massive relief. The $1.52 per share cash payout was a remarkable premium for those who had purchased shares near the all-time lows of $0.33 in early summer. However, for long-term investors who had weathered years of dilution and stock splits, the $1.52 payout represented a fraction of their initial cost basis—a common, bittersweet ending in the micro-cap biotech space.
The acquisition valued Agile's total enterprise at roughly $45 million. This valuation represented a clean exit for Agile’s leadership and allowed Insud Pharma to integrate a highly promising, FDA-approved transdermal patch into its existing women's health portfolio without the burden of Agile’s public company operating expenses.
7. How Former AGRX Shareholders Can Claim Their Payout
If you held agrx stock at the time of the merger's closing on August 26, 2024, you are entitled to receive $1.52 in cash for each share you owned. Because this was a cash-out merger, your shares were automatically converted into the right to receive this payment, and the stock certificates no longer represent ownership in Agile Therapeutics.
Here is how the payout process works depending on how you held your shares:
- Shares Held in a Brokerage Account (Street Name): If you held your agrx stock through an online broker (such as Robinhood, Fidelity, Charles Schwab, E*TRADE, or Webull), you do not need to take any action. Your brokerage should have automatically processed the corporate action, liquidated your shares, and credited your account balance with $1.52 per share in cash. If you have not seen this credit, check your historical account statements for August or September 2024, or contact your broker’s customer service department.
- Registered Shareholders (Stock Certificates): If you held physical stock certificates or had shares registered directly in your name with Agile’s transfer agent, the process is slightly different. You should have received a "Letter of Transmittal" and instructions in the mail shortly after the merger closed. You must complete this letter and return it along with your physical stock certificates to the designated paying agent to claim your cash payout.
- Warrants and Equity Awards: As part of the merger, Agile entered into cash-out acknowledgment agreements with the holders of outstanding warrants. If you held warrants or stock options, their treatment was governed by the specific terms laid out in the June 25, 2024, merger agreement.
Keep in mind that the cash payout is generally treated as a taxable event. Former shareholders should consult with a tax advisor to determine the capital gains or losses they must report on their tax returns relative to their original cost basis.
8. AGRX Stock Frequently Asked Questions (FAQs)
Can I still buy AGRX stock today?
No. AGRX stock was officially delisted and ceased trading on August 26, 2024, following the completion of Agile Therapeutics’ acquisition by Insud Pharma. The company is now private, and shares are no longer available on any public exchange or OTC market.
How much did Agile Therapeutics sell for?
Agile Therapeutics was acquired for an enterprise value of approximately $45 million. Common shareholders received $1.52 per share in cash.
What should I do if I still haven’t received my $1.52 per share payout?
If your shares were held in a brokerage account, contact your broker's corporate actions or customer support team to trace the payment. If you held physical certificates, locate the Letter of Transmittal sent by the paying agent in late 2024 or contact Agile’s historical transfer agent.
Is Twirla still available on the market?
Yes. Twirla is fully available and continues to be marketed and distributed in the United States by Exeltis USA, Inc. (a subsidiary of Insud Pharma). In June 2025, Exeltis renewed its partnership with Afaxys to expand Twirla's availability in public health clinics.
Who is the parent company of Agile Therapeutics now?
Agile Therapeutics is now an indirect, wholly-owned subsidiary of Insud Pharma, S.L., a global pharmaceutical group headquartered in Spain, and operates in conjunction with Exeltis USA, Inc.
Conclusion
The story of agrx stock is a classic cautionary tale of the high-stakes world of biotech investing. While Agile Therapeutics successfully engineered, trialed, and secured FDA approval for a truly innovative product in Twirla, the immense cost of commercialization and regulatory delays proved too heavy for a public micro-cap company to bear.
Ultimately, the August 2024 acquisition by Insud Pharma was a necessary and highly logical step. It salvaged the clinical legacy of Twirla, rewarded patient shareholders with a 356% premium cash buyout, and placed the product in the hands of a global powerhouse with the resources to make it a market success. Though the ticker symbol AGRX has vanished from our trading screens, its impact on women’s reproductive health continues to grow.
